Abrdn Life Sciences Investors (NYSE:HQL) Short Interest Update

Abrdn Life Sciences Investors (NYSE:HQL) was the recipient of a large growth in short interest during the month of November. As of November 15th, there was short interest totalling 74,100 shares, a growth of 17.2% from the October 31st total of 63,200 shares. Based on an average trading volume of 74,100 shares, the days-to-cover ratio is presently 1.0 days.

Institutional Trading of Abrdn Life Sciences Investors

A number of hedge funds have recently bought and sold shares of the business. Future Financial Wealth Managment LLC purchased a new position in Abrdn Life Sciences Investors in the third quarter valued at about $30,000. Ashton Thomas Securities LLC bought a new stake in shares of Abrdn Life Sciences Investors in the 3rd quarter worth approximately $148,000. B. Riley Wealth Advisors Inc. purchased a new position in Abrdn Life Sciences Investors in the first quarter valued at approximately $143,000. Kapstone Financial Advisors LLC bought a new position in Abrdn Life Sciences Investors during the third quarter valued at $177,000. Finally, Sanctuary Advisors LLC purchased a new stake in Abrdn Life Sciences Investors in the second quarter worth $154,000. 32.21% of the stock is currently owned by institutional investors.

Abrdn Life Sciences Investors Stock Up 0.6 %

Abrdn Life Sciences Investors stock traded up $0.09 during midday trading on Tuesday, hitting $14.38. 84,109 shares of the stock were exchanged, compared to its average volume of 92,828. Abrdn Life Sciences Investors has a 52-week low of $12.05 and a 52-week high of $15.90. The business’s 50-day moving average price is $14.74 and its 200-day moving average price is $14.68.

Abrdn Life Sciences Investors Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 10th. Investors of record on Thursday, November 21st will be given a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 13.91%. This is an increase from Abrdn Life Sciences Investors’s previous quarterly dividend of $0.49. The ex-dividend date is Thursday, November 21st.

Abrdn Life Sciences Investors Company Profile

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.